The slowdown in the domestic ultrasound industry trimmedDiasonics Ultrasound revenue last year, although the company reducedits net loss compared to 1992. For the year ended December, Milpitas, CA-based Diasonics reportednet sales of $195.4 million,
The slowdown in the domestic ultrasound industry trimmedDiasonics Ultrasound revenue last year, although the company reducedits net loss compared to 1992.
For the year ended December, Milpitas, CA-based Diasonics reportednet sales of $195.4 million, compared to $205.1 million in 1992.The net loss for the year was $8.5 million, compared to a $22million net loss reported in 1992.
Diasonics reported a break-even fourth quarter, a significantimprovement over the $5.5 million loss reported for the same periodlast year. Net sales for the quarter were $57.2 million, comparedto $62.3 million in the same quarter last year.
In cardiology, revenues increased 20% over last year, primarilydue to European sales of the company's Vingmed CFM cardiologyproduct line, according to president and CEO Bruce N. Moore.
Diasonics last year split its ultrasound business into a separatecompany, apart from former x-ray subsidiary OEC of Salt Lake City(SCAN 2/24/93).
ADAC Laboratories reported that sales of its Genesys Vertexadjustable dual-head gamma camera contributed to a 28% increasein revenue for the first quarter (end-January). Price competitionhas put a strain on profit margins, however, according to thevendor.
ADAC reported revenues for the quarter of $46.5 million, comparedto $36.3 million in the same period a year ago. Income for thequarter was $5.3 million, compared to income of $4.1 million forthe first quarter of 1993, as adjusted for a one-for-three stocksplit in March 1993.
ADAC also reported that it is pleased with the progress ofthe first week of hearings in the patent infringement case filedagainst the firm by competitor Elscint. Elscint's motion for preliminaryinjunction against ADAC is being heard in the U.S. District Courtof Maryland. A trial in the case has been set for October.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.